Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Account Payables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Account Payables for 11 consecutive years, with -$933000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 293.67% to -$933000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 136.42% increase, with the full-year FY2025 number at $1.1 million, up 136.42% from a year prior.
  • Change in Account Payables was -$933000.0 for Q4 2025 at Cartesian Therapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.8 million in Q4 2023 to a low of -$2.4 million in Q3 2024.
  • A 5-year average of $42300.0 and a median of $51500.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 4782.14% in 2021, then surged 4050.0% in 2023.
  • Cartesian Therapeutics' Change in Account Payables stood at -$1.4 million in 2021, then surged by 107.46% to $102000.0 in 2022, then skyrocketed by 2643.14% to $2.8 million in 2023, then crashed by 108.47% to -$237000.0 in 2024, then plummeted by 293.67% to -$933000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Change in Account Payables are -$933000.0 (Q4 2025), $1.8 million (Q3 2025), and -$1.6 million (Q2 2025).